LSP1 and CRIP1 were elevated in exhausted CD8+ T cells, indicating that dual-targeting them may reverse the dysfunction of CD8+ T cells and inhibit leukemia growth to delay disease progression; however, further work is required to be carried out. Here, CRIP1 is linked to leukemia.